Sebastian Burgos Guillermo Montalban-Bravo Lucia Fuente Elias J Jabbour Rashmi Kanagal-Shamanna Kelly A Soltysiak Guillermo Garcia-Manero Maria J Mela-Osorio
10.1097/MD.0000000000014011
Medicine (Baltimore)
2019 Jan;98(1):e14011.
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/30608448/
B-Lymphocytes / pathology Enhancer of Zeste Homolog 2 Protein / genetics Myelodysplastic Syndromes / genetics Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
B-Lymphocytes / pathology Enhancer of Zeste Homolog 2 Protein / genetics Myelodysplastic Syndromes / genetics Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics Case Reports Aged Anemia / complications Angiogenesis Inhibitors / therapeutic use Antineoplastic Agents, Alkylating / therapeutic use Antineoplastic Agents, Hormonal / therapeutic use Bone Marrow / pathology Chromosome Deletion Cyclophosphamide / administration & dosage Cyclophosphamide / therapeutic use Dexamethasone / administration & dosage Dexamethasone / therapeutic use Disease Progression Humans Lenalidomide / administration & dosage Lenalidomide / therapeutic use Male Mutation Myelodysplastic Syndromes / complications Myelodysplastic Syndromes / drug therapy Myelodysplastic Syndromes / pathology Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology Thrombocytopenia / complications Treatment Outcome Angiogenesis Inhibitors Antineoplastic Agents, Alkylating Antineoplastic Agents, Hormonal Dexamethasone Cyclophosphamide EZH2 protein, human Enhancer of Zeste Homolog 2 Protein Lenalidomide
PMC6344201
30608448
Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report
2019